Abstract
Introduction: Sonidegib, a hedgehog pathway inhibitor, is approved to treat patients with locally advanced basal cell carcinoma (BCC) not amenable to curative surgery or radiotherapy. Here we present hematology laboratory shifts in patients with advanced BCC receiving sonidegib 200 mg once daily (QD). Methods BOLT was a randomized, double-blind, multicenter, phase 2 study with patients randomized 1:2 to receive sonidegib 200 or 800 mg orally QD, respectively. Hematology assessments were performed bi-weekly for 14 weeks, then every 4 weeks until week 77, then followed as clinically indicated until end of treatment.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call